Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Ladenstein, Ruth" or (type any "bookEditor issueEditor" and editor="Ladenstein, Ruth")

Add to list
- Journal Article
- A1
- open access
Topotecan-vincristine-doxorubicin in stage 4 high risk neuroblastoma patients failing to achieve a complete metastatic response to rapid COJEC : a SIOPEN study

Loredana Amoroso, Giovanni Erminio, Guy Makin, Andrew DJ Pearson, Penelope Brock, Dominique Valteau-Couanet, Victoria Castel, Marlène Pasquet, Genevieve Laureys (UGent) , Caroline Thomas, et al.

(2018) CANCER RESEARCH AND TREATMENT. 50(1). p.148-155
Add to list
Event-free survival of infants and toddlers enrolled in the HR-NBL-1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis

Maria V Corrias, Stefano Parodi, Andrei Tchirkov, Tim Lammens (UGent) , Ales Vicha, Claudia Pasqualini, Catarina Träger, Yania Yáñez, Sandro Dallorso, Luigi Varesio, et al.

(2018) PEDIATRIC BLOOD & CANCER. 65(7).
Add to list
Risk stratification of high-risk metastatic neuroblastoma : a report from the HR-NBL-1/SIOPEN study

Daniel A Morgenstern, Ulrike Pötschger, Lucas Moreno, Vassilios Papadakis, Cormac Owens, Shifra Ash, Claudia Pasqualini, Roberto Luksch, Alberto Garaventa, Adela Canete, et al.

(2018) PEDIATRIC BLOOD & CANCER. 65(11).
Add to list
Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations : the SIOPEN/HR-NBL1 and COG-A3973 trials

Ruth Ladenstein, Bieke Lambert (UGent) , Ulrike Potschger, Maria-Rita Castellani, Valerie Lewington, Zvi Bar-Sever, Aurore Oudoux, Anna Sliwinska, Katerina Taborska, Lorenzo Biassoni, et al.

(2018) EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 45(2). p.292-305
Add to list
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN) : a multicentre, randomised, phase 3 trial

Ruth Ladenstein, Ulrike Poetschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Isaac Yaniv, Genevieve Laureys (UGent) , Penelope Brock, Jean Marie Michon, Cormac Owens, et al.

(2018) LANCET ONCOLOGY. 19(12). p.1617-1629
Add to list
- Journal Article
- A1
- open access
Genomic amplifications and distal 6q loss : novel markers for poor survival in high-risk neuroblastoma patients

Pauline Depuydt (UGent) , Valentina Boeva, Toby D Hocking, Robrecht Cannoodt (UGent) , Inge M Ambros, Peter F Ambros, Shahab Asgharzadeh, Edward F Attiyeh, Valérie Combaret, Raffaella Defferrari, et al.

(2018) JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 110(10).
Add to list
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN) : an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Andrew D. J. Pearson, Penelope Brock, Roberto Luksch, Victoria Castel, Isaac Yaniv, Vassilios Papadakis, Genevieve Laureys (UGent) , Josef Malis, et al.

(2017) LANCET ONCOLOGY. 18(4). p.500-514
Add to list
- Conference Paper
- C3
Identification of novel, rare markers for poor survival in high-risk neuroblastoma patients by merging and reanalysing existing datasets

Pauline Depuydt (UGent) , Valentina Boeva, Toby Hocking, Robrecht Cannoodt (UGent) , Inge Ambros, Peter Ambros, Shahab Asgharzadeh, Edward Attiyeh, Valérie Combaret, Raffaella Defferrari, et al.

(2017) Big Data in Biology and Health, Abstracts.
Add to list
- Conference Paper
- C3
Genomic amplifications and distal 6q loss are novel markers for poor survival in high-risk neuroblastoma patients

Pauline Depuydt (UGent) , Valentina Boeva, Toby D Hocking, Robrecht Cannoodt (UGent) , Inge M Ambros, Peter F Ambros, Shahab Asgharzadeh, Edward F Attiyeh, Valérie Combaret, Raffaella Defferrari, et al.

(2017) Cancer Genomics, 3rd EACR conference, Abstracts.
Add to list
- Conference Paper
- C3
Distal chromosome 6q deletion defines a group of ultra-high risk neuroblastoma patients

Pauline Depuydt (UGent) , Valentina Boeva, Toby D Hocking, Peter F Ambros, Shahab Asgharzadeh, Edward F Attiyeh, Valérie Combaret, Raffaella Defferrari, Matthias Fischer, Michael D Hogarty, et al.

(2016) Advances in Neuroblastoma Research, Congress abstracts.

Academic Bibliography

Topotecan-vincristine-doxorubicin in stage 4 high risk neuroblastoma patients failing to achieve a complete metastatic response to rapid COJEC : a SIOPEN study

Event-free survival of infants and toddlers enrolled in the HR-NBL-1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis

Risk stratification of high-risk metastatic neuroblastoma : a report from the HR-NBL-1/SIOPEN study

Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations : the SIOPEN/HR-NBL1 and COG-A3973 trials

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN) : a multicentre, randomised, phase 3 trial

Genomic amplifications and distal 6q loss : novel markers for poor survival in high-risk neuroblastoma patients

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN) : an international, randomised, multi-arm, open-label, phase 3 trial

Identification of novel, rare markers for poor survival in high-risk neuroblastoma patients by merging and reanalysing existing datasets

Genomic amplifications and distal 6q loss are novel markers for poor survival in high-risk neuroblastoma patients

Distal chromosome 6q deletion defines a group of ultra-high risk neuroblastoma patients

Contents

Support

Contact